The role of therapeutic apheresis in the treatment of acute antibody-mediated kidney rejection.
Approximately 10% of renal transplant recipients experience acute antibody-mediated rejection (AMR) due to alloimmunization against human leukocyte antigen (HLA) molecules and other antigens. While therapeutic apheresis is included in most treatment protocols for acute kidney allograft rejection, these protocols have been derived mainly from single center experience rather than controlled trials. This concise review focuses on the role of therapeutic apheresis in AMR treatment. Two groups have recently reported treating acute AMR using drug-only strategies without therapeutic apheresis in particular situations, namely in clinically less severe cases or in resource-limited situations without testing for donor specific antibodies. A randomized controlled trial, designed to test the efficacy of immunoadsorption apheresis in AMR treatment, was terminated early and suggested a benefit of apheresis. An observational study suggested efficacy of plasmapheresis in acute AMR treatment, but all patients who received plasmapheresis also received rituximab. As new therapeutic modalities are becoming available, therapeutic apheresis continues to play a role in the treatment of acute kidney allograft rejection.